Abeona ZEVASKYN revenue accelerates 18% to $13.5 million

Abeona Therapeutics (NASDAQ:ABEO) reported third-quarter 2026 net ZEVASKYN revenue of US$13.5 million, an 18% increase from the previous quarter.

Net loss narrowed to US$4.8 million, or US$0.08 per share, from US$20.2 million, or US$0.35 per share, in Q2, while six patient treatments were completed during the quarter.

Abeona had US$134.9 million in cash, cash equivalents and short-term investments at September 30, excluding a subsequent US$30 million private placement, and acquired ABO-801 from Ellodi for US$20 million in common stock, with no upfront cash payment, plus potential milestone payments of US$60 million and tiered royalties.

ZEVASKYN's New Technology Add-On Payment status became effective October 1, 2026, providing eligible hospitals a pathway to receive supplemental Medicare reimbursement for qualifying treatments.

The company has completed 15 ZEVASKYN treatments since launch and expanded its qualified treatment center network to eight sites, while ABO-801 adds a Phase 3-ready oral treatment candidate for eosinophilic esophagitis to its development portfolio.